Baseline characteristics.
| All (N=23) | Control (N=6) | IVIG (N=17) | ||
|---|---|---|---|---|
| Demographics | ||||
| Age at blinatumomab initiation, median, years (range) | 56 (25–74) | 57.5 (50–64) | 48 (25–74) | 0.32 |
| Male | 9 (39.1) | 3 (50) | 6 (35.3) | 0.64 |
| BMI, kg/m2, median (range) | 24.47 (18.48–31.89) | 25.49 (21.84–31.89) | 24.27 (18.48–29.87) | 0.43 |
| Total follow up from blinatumomab initiation, days, median (range) | 393 (108–926) | 354.5 (147–453) | 424 (108–926) | 0.32 |
| Disease characteristics | ||||
| MRD (+)a) | 15 (75) | 5 (83.3) | 10 (71.4) | 1 |
| Relapsed/refractorya) | 5 (25) | 1 (16.7) | 4 (28.6) | 1 |
| Number lines of prior therapy, median (range) | 1 (1–5) | 2 (1–2) | 1 (1–5) | 0.76 |
| Philadelphia chromosome (+) | 7 (30.4) | 1 (16.7) | 6 (35.3) | 0.62 |
| HSCT prior to blinatumomab | 3 (13) | 0 (0) | 3 (17.6) | 0.54 |
| Infectious disease history | ||||
| History of MDR infection | 5 (22.7) | 2 (40) | 3 (17.6) | 0.55 |
| ESBL | 1 (4.3) | 1 (16.7) | 0 (0) | 0.26 |
| MRSE | 4 (17.4) | 1 (16.7) | 3 (17.6) | 1 |
| Hypogammaglobulinemia Risk factors | ||||
| Prior anti-CD20 therapy | 10 (43.5) | 2 (33.3) | 8 (47.1) | 0.66 |
| Number of doses, median (range) | 3.5 (1–7) | 6.5 (6–7) | 3 (1–5) | 0.04 |
| Multiple myeloma | 1 (4.3) | 0 (0) | 1 (5.9) | 1 |
All values listed as N (%) unless otherwise noted.
a)Excluding 3 patients who received blinatumomab for consolidation/maintenance therapy.
Abbreviations: BMI, body mass index; ESBL, extended spectrum beta-lactamase; HSCT, hematopoietic stem cell transplant; MDR, multidrug resistant organism; MRD, minimal residual disease; MRSE, methicillin-resistant staphylococcus epidermidis.
Blood Res 2022;57:135~143 https://doi.org/10.5045/br.2022.2021163
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd